The University of Southampton
University of Southampton Institutional Repository

Identifying the lowest effective dose of acetazolamide for the prophylaxis of acute mountain sickness: systematic review and meta-analysis

Low, Emma V., Avery, Anthony J., Gupta, Vaibhav, Schedlbauer, Angela and Grocott, Michael P.W. (2012) Identifying the lowest effective dose of acetazolamide for the prophylaxis of acute mountain sickness: systematic review and meta-analysis BMJ, 345, e6779. (doi:10.1136/bmj.e6779). (PMID:23081689).

Record type: Article

Abstract

OBJECTIVES: To assess the efficacy of three different daily doses of acetazolamide in the prevention of acute mountain sickness and to determine the lowest effective dose.

DESIGN: Systematic review and meta-analysis.

DATA SOURCES: Medline and Embase along with a hand search of selected bibliographies. No language restrictions were applied.

STUDY SELECTION: Randomised controlled trials assessing the use of acetazolamide at 250 mg, 500 mg, or 750 mg daily versus placebo in adults as a drug intervention for the prophylaxis of acute mountain sickness. Included studies were required to state the administered dose of acetazolamide and to randomise participants before ascent to either acetazolamide or placebo. Two reviewers independently carried out the selection process.

DATA EXTRACTION: Two reviewers extracted data concerning study methods, pharmacological intervention with acetazolamide, method of assessment of acute mountain sickness, and event rates in both control and intervention groups, which were verified and analysed by the review team collaboratively.

DATA SYNTHESIS: 11 studies (with 12 interventions arms) were included in the review. Acetazolamide at doses of 250 mg, 500 mg, and 750 mg were all effective in preventing acute mountain sickness above 3000 m, with a combined odds ratio of 0.36 (95% confidence interval 0.28 to 0.46). At a dose of 250 mg daily the number needed to treat for acetazolamide to prevent acute mountain sickness was 6 (95% confidence interval 5 to 11). Heterogeneity ranged from I(2)=0% (500 mg subgroup) to I(2)=44% (750 mg subgroup).

CONCLUSIONS: Acetazolamide in doses of 250 mg, 500 mg, and 750 mg daily are all more effective than placebo for preventing acute mountain sickness. Acetazolamide 250 mg daily is the lowest effective dose to prevent acute mountain sickness for which evidence is available.

Full text not available from this repository.

More information

Published date: 18 October 2012
Organisations: Human Development & Health

Identifiers

Local EPrints ID: 348854
URI: http://eprints.soton.ac.uk/id/eprint/348854
ISSN: 0959-8138
PURE UUID: 7d45b3ef-d0ca-41f1-9d7c-b632364ca16e

Catalogue record

Date deposited: 20 Feb 2013 15:28
Last modified: 08 Sep 2017 16:33

Export record

Altmetrics

Contributors

Author: Emma V. Low
Author: Anthony J. Avery
Author: Vaibhav Gupta
Author: Angela Schedlbauer

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×